Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidanc...(symptoms in adults and met all safety an...)

- By June 30, 2008 Shire had agreements with nine of its top eleven

managed care organizations for VYVANSE.

- On July 2, 2008 Shire shipped to wholesalers stocks of three additional

dosage strengths (20mg, 40mg and 60mg) for VYVANSE representing product

sales of approximately $24 million. These product sales will be

recognized into revenue in Q3 2008.

LIALDA(R)/MEZAVANT - Ulcerative Colitis

- On April 1, 2008 the product was launched in Ireland as MEZAVANT XL

and, following approval in Luxembourg on June 26, 2008, is now approved

in 15 countries. Further launches are planned in certain other EU

countries during 2008, subject to the successful conclusion of pricing

and reimbursement negotiations.

- During April 2008, TAP Pharmaceutical Products Inc. ("TAP") commenced

co-promotion of LIALDA in the US in accordance with the co-promotion

agreement entered into on March 26, 2008. This agreement adds more than

500 additional sales representatives from TAP which will increase the

reach and frequency of sales calls covering an additional 22,000

doctors.

FOSRENOL - Hyperphosphatemia

- Following the launch of the product in Slovenia and Switzerland during

the second quarter of 2008 and in Malta and Malaysia in July 2008,

FOSRENOL is now available in 29 countries.

ELAPRASE(R) - Hunter syndrome

- During the three months to June 30, 2008 ELAPRASE was approved for

commercial sale in Brazil. ELAPRASE is now approved in 40 countries

worldwide.

Pipeline Highlights

INTUNIV(TM) - ADHD

- On May 8, 2008 Shire announced pivotal trial results for INTUNIV which

is in registration in the US. The data demonstrated that INTUNIV has

significant efficacy in reducing ADHD symptoms for patients taking
'/>"/>